These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

716 related articles for article (PubMed ID: 16234499)

  • 1. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
    Nanda R; Schumm LP; Cummings S; Fackenthal JD; Sveen L; Ademuyiwa F; Cobleigh M; Esserman L; Lindor NM; Neuhausen SL; Olopade OI
    JAMA; 2005 Oct; 294(15):1925-33. PubMed ID: 16234499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model.
    Vogel KJ; Atchley DP; Erlichman J; Broglio KR; Ready KJ; Valero V; Amos CI; Hortobagyi GN; Lu KH; Arun B
    J Clin Oncol; 2007 Oct; 25(29):4635-41. PubMed ID: 17925560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States.
    Huo D; Senie RT; Daly M; Buys SS; Cummings S; Ogutha J; Hope K; Olopade OI
    J Clin Oncol; 2009 Mar; 27(8):1184-90. PubMed ID: 19188678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer.
    Armstrong K; Micco E; Carney A; Stopfer J; Putt M
    JAMA; 2005 Apr; 293(14):1729-36. PubMed ID: 15827311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.
    Hall MJ; Reid JE; Burbidge LA; Pruss D; Deffenbaugh AM; Frye C; Wenstrup RJ; Ward BE; Scholl TA; Noll WW
    Cancer; 2009 May; 115(10):2222-33. PubMed ID: 19241424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry.
    Kurian AW; Gong GD; John EM; Miron A; Felberg A; Phipps AI; West DW; Whittemore AS
    Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1084-91. PubMed ID: 19336551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1 and BRCA2 mutations in a study of African American breast cancer patients.
    Pal T; Permuth-Wey J; Holtje T; Sutphen R
    Cancer Epidemiol Biomarkers Prev; 2004 Nov; 13(11 Pt 1):1794-9. PubMed ID: 15533909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to white women.
    Haffty BG; Silber A; Matloff E; Chung J; Lannin D
    J Med Genet; 2006 Feb; 43(2):133-7. PubMed ID: 15983021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium.
    Fischer C; Kuchenbäcker K; Engel C; Zachariae S; Rhiem K; Meindl A; Rahner N; Dikow N; Plendl H; Debatin I; Grimm T; Gadzicki D; Flöttmann R; Horvath J; Schröck E; Stock F; Schäfer D; Schwaab I; Kartsonaki C; Mavaddat N; Schlegelberger B; Antoniou AC; Schmutzler R;
    J Med Genet; 2013 Jun; 50(6):360-7. PubMed ID: 23564750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years.
    Malone KE; Daling JR; Doody DR; Hsu L; Bernstein L; Coates RJ; Marchbanks PA; Simon MS; McDonald JA; Norman SA; Strom BL; Burkman RT; Ursin G; Deapen D; Weiss LK; Folger S; Madeoy JJ; Friedrichsen DM; Suter NM; Humphrey MC; Spirtas R; Ostrander EA
    Cancer Res; 2006 Aug; 66(16):8297-308. PubMed ID: 16912212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women.
    Newman B; Mu H; Butler LM; Millikan RC; Moorman PG; King MC
    JAMA; 1998 Mar; 279(12):915-21. PubMed ID: 9544765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2.
    Schubert EL; Lee MK; Mefford HC; Argonza RH; Morrow JE; Hull J; Dann JL; King MC
    Am J Hum Genet; 1997 May; 60(5):1031-40. PubMed ID: 9150150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2.
    Jackson SA; Davis AA; Li J; Yi N; McCormick SR; Grant C; Fallen T; Crawford B; Loranger K; Litton J; Arun B; Vande Wydeven K; Sidani A; Farmer K; Sanders M; Hoskins K; Nussbaum R; Esserman L; Garber JE; Kaklamani VG;
    Cancer; 2014 May; 120(10):1557-64. PubMed ID: 24522996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
    Eoh KJ; Park JS; Park HS; Lee ST; Han J; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ
    Gynecol Oncol; 2017 Apr; 145(1):137-141. PubMed ID: 28159408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer genetics in African Americans.
    Olopade OI; Fackenthal JD; Dunston G; Tainsky MA; Collins F; Whitfield-Broome C
    Cancer; 2003 Jan; 97(1 Suppl):236-45. PubMed ID: 12491487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population.
    Lavie O; Narod S; Lejbkowicz F; Dishon S; Goldberg Y; Gemer O; Rennert G
    Ann Oncol; 2011 Apr; 22(4):964-966. PubMed ID: 20924075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families.
    Palma MD; Domchek SM; Stopfer J; Erlichman J; Siegfried JD; Tigges-Cardwell J; Mason BA; Rebbeck TR; Nathanson KL
    Cancer Res; 2008 Sep; 68(17):7006-14. PubMed ID: 18703817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.